Barclays’s Immune Pharmaceuticals Inc. IMNP Stock Holding History

Barclays’s Portfolio IMNP Stock Details IMNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-187,059	Closed	-$35K	–	7663
2018 Q2	$35K	Buy	187,059 +90,271	+93%	+$25.5K	﹤0.01%	5878
2018 Q1	$34K	Buy	+96,788	New	+$46.1K	﹤0.01%	6182
2017 Q3	–	Sell	-278	Closed	-$1K	–	7225
2017 Q2	$1K	Buy	+278	New	+$747	﹤0.01%	6581

Other funds holding IMNP

Intellectus Partners San Francisco, California $490M AUM 35.11% 1-Year Est. Return

Barclays's IMNP Position: Q3 2018 in Review

Barclays sold out of Immune Pharmaceuticals Inc. (IMNP) in Q3 2018, closing a stake of 187,059 shares — an estimated $35K sold.

Barclays first reported a position in IMNP in Q2 2017 and held it in 3 quarters. The position peaked at $35K in Q2 2018. 1 fund tracked by Wall St. Rank holds IMNP as of Q3 2018.

Barclays reported no remaining Immune Pharmaceuticals Inc. position as of Q3 2018 after selling out during the quarter.
Barclays sold 187,059 Immune Pharmaceuticals Inc. shares in Q3 2018, an estimated $35K.
Barclays first reported a position in Immune Pharmaceuticals Inc. in Q2 2017 and held it in 3 quarters.
Barclays's Immune Pharmaceuticals Inc. position peaked at $35K in Q2 2018.
1 fund tracked by Wall St. Rank held Immune Pharmaceuticals Inc. as of Q3 2018.

Based on Barclays's 13F filing for Q3 2018, filed 14 Nov 2018.